Resistell starts research project with Pfizer

Congratulations to our portfolio company Resistell for entering into a research project with the US-pharmaceutical company Pfizer. Goal of this project is to provide a pre-clinical proof of concept of Resistell’s Antibiotic Susceptibility Test for a novel antibiotic.

Multi-drug resistant bacterial infections represent a key challenge for today’s global healthcare systems. Resistell is developing the world’s fastest Antibiotic Susceptibility Test which provides highly accurate results in just four hours, thereby setting a new industry benchmark.

A positive outcome of the research project may contribute to a paradigm shift in the treatment of bacterial infections. This could help healthcare professional to improve therapy decisions and drastically enhance patient treatment.

More information in the press release under the following Link.

More about Resistell

Follow-up investment in Hemotune Overview Welcome Olivia
Want to learn more about OCCIDENT?